News

After a court case rehashes the issue of excessive secrecy in trial data, drug firms maintain their objections over releasing data on their products.

The time to stop hammering square pegs into round holes in terms of design strategy has come, as sponsors embrace an adaptive supply chain approach.

Darren Davis, Senior Vice President at Precision for Medicine, explores the need for specialty labs in cancer treatment plans.

As a new industry survey shows, factoring in a generational cohort surfaces some provocative results related to key health indicators in clinical outsourcing relationships.

The latest happenings in the clinical trials industry, all in one place.

Executive Medical Director of Oncology for Premier Research, Emile Youssef, discusses crucial challenges that must be addressed in order to fulfill the promise of precision oncology.